Caleo Biotechnologies
Caleo Biotechnologies develops patient-derived human translational models for preclinical therapeutic development. Our proprietary Organ-Dish™ platform generates multicellular 3D tissue models directly from human biospecimens while preserving key epithelial, stromal/mesenchymal, and immune compartments and features of native tissue biology. The platform enables evaluation of therapeutic efficacy, tissue injury and repair, inflammation, immune response, fibrosis and remodeling, and translational biomarkers in a patient-relevant human system. Organ-Dish™ models are scalable and compatible with pharmacologic, biologic, and cell-based therapeutic testing and downstream molecular and histologic analyses. Our approach aligns with the FDA’s increasing emphasis on human-relevant New Approach Methodologies (NAMs) to strengthen preclinical evidence and reduce reliance on animal testing. CaleoBio is interested in partnerships with therapeutic developers, biotechnology companies, academic investigators, and government/DoD teams seeking human translational models to support preclinical R&D and therapeutic development. Current and expanding applications include gastrointestinal disease, traumatic and complex wounds, pulmonary fibrosis, liver disease, and oncology.
Industries
Nr. of Employees
small (1-50)
Caleo Biotechnologies
20271 GoldenRod Ln, Germantown, MD 20876
Caleo Biotechnologies is currently seeking investment
Caleo Biotechnologies is seeking a seed investment in the range of 1m-5m
Products
Organ-Dish™ Patient-Derived Human Translational Model Platform
Proprietary platform for generating multicellular 3D human tissue models directly from patient biospecimens while preserving key epithelial, stromal/mesenchymal, and immune compartments. Organ-Dish™ models support preclinical evaluation of therapeutic efficacy, tissue injury and repair, inflammation, immune response, fibrosis/remodeling, and translational biomarkers.
Organ-Dish™ Patient-Derived Human Translational Model Platform
Proprietary platform for generating multicellular 3D human tissue models directly from patient biospecimens while preserving key epithelial, stromal/mesenchymal, and immune compartments. Organ-Dish™ models support preclinical evaluation of therapeutic efficacy, tissue injury and repair, inflammation, immune response, fibrosis/remodeling, and translational biomarkers.
Services
Preclinical Therapeutic Evaluation
Evaluation of small molecules, biologics, cell-based therapies, and other therapeutic candidates in patient-derived Organ-Dish™ models using functional, molecular, and histologic endpoints.
Human Translational Model Development
Development and adaptation of patient-derived 3D tissue models for disease- and application-specific preclinical research, including inflammatory, fibrotic, wound/trauma, gastrointestinal, and oncology applications.
Therapeutic Response & Biomarker Analysis
Assessment of therapeutic response using tissue viability, inflammation, immune response, tissue injury/repair, histology, immunohistochemistry, and molecular biomarker analyses.
Custom Preclinical Studies & Collaborative R&D
Collaborative study design and execution integrating Organ-Dish™ models into therapeutic-development programs to generate human translational evidence and support candidate evaluation.
Preclinical Therapeutic Evaluation
Evaluation of small molecules, biologics, cell-based therapies, and other therapeutic candidates in patient-derived Organ-Dish™ models using functional, molecular, and histologic endpoints.
Human Translational Model Development
Development and adaptation of patient-derived 3D tissue models for disease- and application-specific preclinical research, including inflammatory, fibrotic, wound/trauma, gastrointestinal, and oncology applications.
Therapeutic Response & Biomarker Analysis
Assessment of therapeutic response using tissue viability, inflammation, immune response, tissue injury/repair, histology, immunohistochemistry, and molecular biomarker analyses.
Custom Preclinical Studies & Collaborative R&D
Collaborative study design and execution integrating Organ-Dish™ models into therapeutic-development programs to generate human translational evidence and support candidate evaluation.
Expertise Areas
- Human translational preclinical modeling, Patient-derived disease modeling, Therapeutic efficacy testing, 3D tissue modeling, Tissue engineering, Tissue injury and repair, Inflammation and immunology, Fibrosis and tissue remodeling
Key Technologies
- Organ-Dish™ Technology, Patient-Derived 3D Tissue Models, Multicellular & Immune-Competent Models, Ex Vivo Tissue Modeling, Translational Therapeutic Testing, Molecular Biomarker Analysis
Key People
News & Updates
Article discussing the limitations of current fibrosis models and showing how advanced tissue models enable the study of dynamic multicellular interactions driving disease.
Describes the preservation of immune, stromal, and epithelial components in ex vivo tissue models, supporting high-resolution studies of inflammation and fibrosis.
Demonstrates that transplanted tissue models retain phenotypic and functional characteristics of the original patient tissue.
Outlines the critical need for predictive, clinically relevant preclinical models to improve drug discovery outcomes.
Article discussing the limitations of current fibrosis models and showing how advanced tissue models enable the study of dynamic multicellular interactions driving disease.
Describes the preservation of immune, stromal, and epithelial components in ex vivo tissue models, supporting high-resolution studies of inflammation and fibrosis.
Demonstrates that transplanted tissue models retain phenotypic and functional characteristics of the original patient tissue.
Outlines the critical need for predictive, clinically relevant preclinical models to improve drug discovery outcomes.